Here’s What the Street Thinks About Eli Lilly and Company (LLY)
Key takeaways
- Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25.
- The company will also be entitled to tiered mid-single-digit royalties on future global product sales if the product reaches the market.
- Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products.
Here’s What the Street Thinks About Eli Lilly and Company (LLY) Noor Ul Ain Rehman Sun, June 28, 2026 at 1:36 AM GMT+7 1 min read LLY BIOA-B.ST Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares.
In a separate development, Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management stated that BioArctic will receive USD 30 million in upfront payment as part of the agreement, and will be eligible to receive additional milestone payments of up to USD 770 million in addition to the upfront payment. The company will also be entitled to tiered mid-single-digit royalties on future global product sales if the product reaches the market.
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.